Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2023-07-25 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
独立董事对公司第九届董事会第十七次会议相关议案发表的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on several proposals related to the company's 2022 restricted stock incentive plan, including the lifting of lock-up conditions, adjustment of repurchase prices, and repurchase cancellation of restricted stocks. It references compliance with stock exchange listing rules and company articles of association. The content focuses on governance and approval of stock incentive plan matters, which are typically part of board or management information disclosures. The document is short (1187 characters) and does not contain financial statements or detailed financial data, nor is it an announcement of voting results or a proxy solicitation. It is not an annual or interim report, nor an earnings release. Therefore, the best fitting category is Board/Management Information (MANG), as it relates to board meeting proposals and independent directors' opinions on governance matters.
2023-07-25 Chinese
关于拟回购注销2022年限制性股票激励计划部分已获授但尚未解除限售的限制性股票的公告
Transaction in Own Shares Classification · 95% confidence The document is an official announcement from a company regarding the proposed repurchase and cancellation of part of its 2022 restricted stock incentive plan shares. It details the background, reasons, quantities, prices, and approvals related to the stock repurchase and cancellation. The document includes board and supervisory committee meeting resolutions, independent director opinions, and legal opinions. It is a regulatory announcement about a share repurchase related to an employee stock incentive plan, not a full financial report or earnings release. It does not contain financial statements or detailed financial analysis but focuses on corporate actions related to share capital changes. Therefore, it fits best under the category of Transaction in Own Shares (POS), which covers company buybacks or cancellations of its own shares.
2023-07-25 Chinese
第九届董事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the 17th meeting of the 9th Board of Directors of Dongbei Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, voting results on various proposals related to stock incentive plans and a proposed shareholders meeting. The document does not contain financial statements or detailed financial analysis but rather reports on board decisions and voting outcomes. It is not a full annual or interim report, nor an earnings release or audit report. It is not a proxy solicitation or AGM information but specifically relates to board meeting resolutions. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board meeting resolutions, confirming this classification with high confidence.
2023-07-25 Chinese
第九届监事会第十三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Dongbei Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, voting results on specific agenda items related to the 2022 restricted stock incentive plan, and references other related announcements. The document is short (1010 characters) and primarily serves as an official announcement of meeting resolutions rather than a full report or detailed financial disclosure. It does not contain financial statements or detailed management discussion. It is not a full Annual Report, Interim Report, or Earnings Release. It is not a proxy solicitation or voting results announcement from a shareholder meeting but from the Supervisory Board meeting. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement of board resolutions and related disclosures that do not fit other specific categories.
2023-07-25 Chinese
关于董事辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company director, Mr. Guo Qiyong, from his position on the board and related committees. It details the resignation reason, confirms compliance with legal requirements, and mentions the director's shareholding and adherence to regulations post-resignation. There is no financial data, report, or presentation content. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2023-07-03 Chinese
关于公司产品上市申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a product listing application by a regulatory authority (National Medical Products Administration). It details the approval of a drug product (Vildagliptin) for production and marketing. The document is short (930 characters) and serves as an official announcement of regulatory approval rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or other report content. It is not an annual report, earnings release, or any other detailed financial or governance report. Therefore, it fits best as a Regulatory Filing (RNS), which is a general category for regulatory announcements and compliance documents that do not fit other specific categories.
2023-05-08 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.